The antiandrogen withdrawal syndrome in relapsed prostate cancer.
Level V
Where this comes from
- Record sourced from PubMed, PMID 9074903.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Evolving data suggest that palliation of relapsed prostate cancer can be achieved by the selective discontinuation of agents that act via steroid hormone receptors. Clinical benefit has been observed following the withdrawal of flutamide (Eulexin, Schering-Plough International), bicalutamide (Casodex, Zeneca Ltd), oestrogens, progestational agents and retinoids. For patients with progression of disease while receiving these drugs, a period of observation after withdrawal should be considered before further therapy is initiated.
Medical subject headings
- Androgen Antagonists
- Antineoplastic Agents, Hormonal
- Palliative Care
- Prostatic Neoplasms